Hib-DTP-poliovirus vaccine (EasyfourPol) - Panacea Biotec

Drug Profile

Hib-DTP-poliovirus vaccine (EasyfourPol) - Panacea Biotec

Alternative Names: DTwP-Hib-IPV vaccine - Panacea Biotec; DTwP-Hib-poliovirus vaccine - Panacea Biotec; Easyfour Pol; EasyfourPol

Latest Information Update: 29 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Panacea Biotec
  • Class Haemophilus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 25 Jul 2016 Panacea Biotec initiates a phase II/III trial in Diphtheria, Tetanus, Pertussis in India (Prevention) (IM) (CTRI/2016/07/007078)
  • 14 Mar 2016 Hib-DTP-poliovirus vaccine is still in phase III trials in India
  • 28 Feb 2011 Phase-II/III clinical trials in Diphtheria, Tetanus, Pertussis, Haemophilus infections and Poliomyelitis (Prevention) in India (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top